Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human ...

The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...

GSK will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs.The British pharma giant said Wednesday that it will pay the ...

British pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in ...

45. LONDON — GSK said Wednesday it would purchase an experimental liver disease medicine from Boston Pharmaceuticals for $1.2 billion upfront, seeking to build up its pipeline of future medicines.

ORLANDO, FL / ACCESS Newswire / June 6, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Liberty Star Minerals… June 6, 2025 Positive Interim ...

GSK GSK-0.07%decrease; red down pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs.

2025 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), an emerging leader in age-reversal science, today announced its participation in the BIO International ...

The treatment, made by Boston Pharmaceuticals, is ready to enter the last stage of clinical tests, the UK drugmaker said Wednesday. The medicine could become a blockbuster, according to analysts ...